Forest Laboratories Inc

Forest Laboratories — Proxy Contest (July 2011)

35 slides from Forest Laboratories's proxy contest presentation, Jul 27, 2011

  1. Slide 1: Schedule 14A Proxy Statement

    SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [ ] Filed by a Party other than the Registrant [X] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as pe

  2. Slide 2: Filing fee information

    [X] No fee required. [ ] Fee computed on table below per Exchange Act Rule 14a-6(i)(4) and 0-11. 1) Title of each class of securities to which transaction applies: 2) Aggregate number of securities to which transaction applies: 3) Per unit price or other underlying value of transaction computed purs

  3. Slide 3: Notice of definitive proxy statement filing

    ON JULY 19, 2011, THE PARTICIPANTS (AS DEFINED BELOW) FILED A DEFINITIVE PROXY STATEMENT WITH THE SECURITIES AND EXCHANGE COMMISSION. SECURITY HOLDERS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER DOCUMENTS RELATED TO THE SOLICITATION OF PROXIES BY CARL C. ICAHN, DR. ALEXANDER J. DENN

  4. Slide 4: Forest Laboratories Investor Presentation July 2011

    Forest Investor July 2011 Laboratories Presentation

  5. Slide 5: Special note regarding presentation

    Special •This guarantee include •Many any •Sections Amylin However, •All stockholders proxy Stockholders upon 2 such stockholders request. presentation along of note their Pharmaceuticals, beliefs. of the their thethis regarding with information of statements call Information accuracy success Forest

  6. Slide 6: Agenda

    •Agenda 3 Executive Forest Change Icahn nominees Labs needed Summary poorly at will board positioned add of valuable directors for future experience success

  7. Slide 7: Executive Summary

    Forest -Lexapro -Government •-Current -Icahn Support 4 ForestLaboratories nominees representation Labs the directors andIcahn at needs seeking Namenda critical have nominees have needs independent will to succeeded not juncture patent exclude benefit Icahn recognized andexpirations nominees vote and

  8. Slide 8: Agenda: Forest Labs poorly positioned for future success

    •Agenda 5 Executive Forest Change Icahn nominees Labs needed Summary poorly at will board positioned add of valuable directors for future experience success

  9. Slide 9: Patent expirations create significant headwinds

    Note: Source: A 6 2,000 3,000 4,000 $5,000M -$2,038M Growth $1,045M Annual Other $3,220M $ 0 500 1,000 $1,500M -$1,144M FY11A Lexapro FY13E $252M 4,213M 1,396M nnualFiscal product operating Analyst in patent and Other year Namenda expiration sales research; Products ends profit ($M) March patent ($M

  10. Slide 10: Government actions and settlement

    Government •Department -Revenue •Company -$313M •Forest -Question •Board Independent Note: Source: D 7 $ 0 100 200 300 $400M Payment $149M Forfeiture $14M Fine Total $313M 150M oJ - USAtty DoJ and Labs Public of toand independence –responded settlement management federal USAtty and revenue recently

  11. Slide 11: Management departures and succession concerns

    •Board Recent Company P 8 Marketing/Commercial CFO COO President CEO Scientific Corporate Kenneth John Lawrence Office Howard ?F Elaine Marco David osition rancis President ManyEggers responsible Solomon Holder Hochberg Taglietti departure investors Perier Solomon Goodman Affairs/R&D has Olanoff Dev

  12. Slide 12: Management tenure and legal issues

    Management DoJ Health •State NYSE Note: Source: 9 As Various Subsidiary Received Department Forest Defendants Currently Defending Defendant Entered Publicly –a& DoJ result, USAtty Agencies Federal Public Labs government into reprimanded –subpoena defending in class USAtty pled FRX in tenure admitted

  13. Slide 13: Scattered therapeutic areas may not fill the gap

    Note: Source: Central Gastro-enterology 10 OB Endocrinology Anti-Infective Cardiovascular Pain Scattered Respiratory / Management GYN ($M) Nervous Public efforts Pediatric represents documents across System FYtherapeutic 8 therapeutic 2011 salesareas ending areasmayMarch not fill31gap or (current fr

  14. Slide 14: SG&A spending versus specialty pharma peers

    Currently, Note: FRX=Forest Source: 2010 11 4 0 10 20 30 40 50% WPI 17% MYL 19% VRX 20% FRX 30% ENDP 31% CEPH 34% WCRX 37% SHP 39% AGN 0% SG&A FRX Analyst Forest represents % Labs, of research; Labs net VRX=Valeant sales FY11 SG&A Public ending spending documents Pharmaceuticals, March; in line SG&A

  15. Slide 15: SG&A versus Big Pharma peers

    Similar Note: MRK=Merck, Source: 2010 12 3 0 5 10 15 20 25 30 35% BMY 24% SAN 25% ABT 27% MRK 28% PFE 29% GSK FRX BAY AZN 30% LLY 31% NVS 1% SG&A FRX situation Analyst represents margin AABT=Abbot research; when % Forest FY11 Public ending Labs, Labsdocuments compared BMY=Bristol-Myers March; SG&A w

  16. Slide 16: Lexapro patent expiration will severely impact profitability

    However, FY Net Cost COGS SG&A R&D Operating Note: other Source: 13 2011 sales of income 600 % COGS % 1,254 goods Analyst of FRX ($M) of Lexapro 0margin Expenses Income sales 600 sales allocated 394 $964 -Lexapro $4,213 research; 14% 859 23% % 30% $1,396 patent $530 $2,817 33% 0% $2,316 by 23% 17% =

  17. Slide 17: Excluding Lexapro, Forest spends more on SG&A

    Excluding Note: Source: 2010 14 4 0 10 20 30 40 50% WPI 17% MYL 19% VRX 20% ENDP 31% CEPH 34% WCRX 37% SHP 39% AGN 40% FRX 5% SG&A FRX Analyst Lexapro, excludes % ofresearch; netForest Lexapro salesPublic Labs making spends documents same more assumptions on SG&A than as prior Specialty slide and Ph

  18. Slide 18: Similar situation versus Big Pharma peer group

    Similar 2010 50% 45% FRX Note: Source: 15 40 31% NVS SG&A FRX situation Analyst 3031% LLY 20 excludes margin 10 30% AZN research; as 0 Forest % 30% Lexapro BAY30% Public Labs GSK making 29% spends PFE documents 28% MRK same more 27% assumptions ABT on25% SG&A SAN 24%BMY than as prior Big slide Pharm

  19. Slide 19: Agenda: Change needed at board

    •Agenda 16 Executive Forest Change Icahn nominees Labs needed Summary poorly at will board positioned add of valuable directors for future experience success

  20. Slide 20: Market value destroyed over last seven years

    Value Market Equity Change $4.3B Note: 17 destroyed value in value ($B) cap. over ($M) = $30B average last -$17.3B 20 ~710 years, of 0$11.4B high $26.6B average and $3.4B low March tenure stock $1.7B 2004 of price $1.7B newest market in $1.4B quarter directors cap. $9.3B x diluted March shares 2011

  21. Slide 21: Forest lost value while peers gained

    ForestWPI 150% -65% FRX Change Note: Public 18 34% Change 100 Labs documents in CEPH value 50 47% lost 0in-50 50% value, % ($B) value ENDP -100 52% -$17B while represents MYL 103% $2B peers AGN $2B change gained $1Bin substantial $3B market $11Bcapitalization value over same fromperiod March 2004 to

  22. Slide 22: Chairman and CEO compensation

    Chairman $10M $9.0M FY Salary Bonus Stock Options While Note: Source: 19 2004 Fiscal 8Forest $7.0M Public 6FY 4& and 2year CEO 2005 Labs 0$6.7M CEO documents ends Solomon FY equity Solomon $5.4M 2006 March value FY compensation $6.5M compensation 312007 declined $6.6M FY by 2008 ($M) $8.3M ~65%, not

  23. Slide 23: Current Forest board of directors

    PriorGoldwasser Name Howard (1964) Lawrence Nesli William George Dan Kenneth Lester Director Peter Associate Forest Note: Source: 20 to Zimetbaum Basgoz *Inside Tenure Salans Labs Chairman, Cohan Icahn ISS; Solomon Candee of Goodman Chief Professor, Olanoff Clinical acknowledged Public 513 (year dir

  24. Slide 24: Reasons for board change

    However, Director Howard Dan Kenneth •Lester Icahn 21OIG-HHS Multiple Responsible No Goldwasser operational other nominees Salans Solomon Reason Goodman more adverse recent may •for No director will to experience •exclude public company’s •Length civil, operational Replace •Length provide Former cha

  25. Slide 25: Forest board statements and facts

    Current Forest “Forest’s four •Forest “Mr. •Alex Howard Kenneth Presiding Board’s Source: 22 candidates Icahn’s Denner Board Board board Forest “careful” Solomon, Goodman, Board Independent nominees Statement and has not Labs are has review receptive not Richard Chairman far carefully letter intervi

  26. Slide 26: Chairman Solomon stock sales

    Chairman 20M 15 13M 11M 10 5 2003 Sale Solomon Note: Source: 2306M 15M 0Tax 11M $600M 400 2004 Tax 7M Public $490M Gift shares reduced represents and 2005 6MTotal CEO documents 5M $42M owned 2006 ownership 4M Solomon’s stock 2007 $22M 200 (M)used 2008 Solmon by $554M investment for ~2009 75% tax sto

  27. Slide 27: Icahn ownership versus management alignment

    Icahn FRX 20M 5 10 15 0 % Note: Source: 243.6M Icahn of 19.9M o/s shares parties Howard 3.5M Parties Public shares owned much Solomon’s documents All 7.2% other more (M) 1.3%directors aligned 3.5M 1.3%shares with and all executives owned shareholders includes Howardthan 2.3M Solomon management optio

  28. Slide 28: Agenda: Icahn nominees will add valuable experience

    •Agenda 25 Executive Forest Change Icahn nominees Labs needed Summary poorly at will board positioned add of valuable directors for future experience success

  29. Slide 29: Icahn nominees backgrounds

    IcahnEnde Name Alexander Richard Eric America, Former Lucian Finance Renowned Current 26 nominees Background Bebchuk senior director director Mulligan and Lehman Co-founder, Denner corporate Director biotechnology at will at William Mallinckrodt Brothers ImClone Genzyme Managing Biogen Mesa OJSC lev

  30. Slide 30: Share price appreciation on biopharma boards

    Icahn Share 25 50 75 100 125% 0 Months Note: Pharmaceuticals, Source: 27AMLN 14%nominees price Share Public to 42% ENZN realize appreciation price 62% documents on GENZ GENZ=Genzyme, 26 97% appreciation biopharma 26 102% IMCL 10 % 31 26 boards BIIB represents BIIB=Biogen help change create value Ide

  31. Slide 31: Denner and Mulligan at ImClone

    Denner •Partner Source: 28 Took Recharged Industry ImClone Settled Initiated Exec. Removed From Margin Significantly Cancelled Increased Pipeline steps 2005 Committee Relations and public litigation expansion cited dialogue, had cost morale spending substantial programs Mulligan partner to topoor in

  32. Slide 32: Icahn nominees at Biogen Idec

    Icahn •dramatic Source: 29 Alex Worked Partnered Board Collaborated nominees Denner empowered Public acceleration together with and documents with collaborated existing with Richard management existing ofexisting clinical board Mulligan with board members board activities to existing members examine

  33. Slide 33: Icahn nominees at Genzyme, Enzon and Amylin

    Icahn Genzyme Operational R&D Other •Metreleptin Source: 30 Sold nominees •company Executed Examined Public Enzon • Reduced documents worked •Amylin three Declassified multiple spending business within-licensing existing board divestitures by $350M directors opportunities ••Reduced Sold to drive pha

  34. Slide 34: Icahn nominees' focus

    • Accelerate Icahn 31Focus Examine Share Ensure Maximize nominees best company investor cost return practices development structure have will interests on ofseek strategic capital several fromand to and represented director generate to identify proposals therapeutic adoption shareholders experience

  35. Slide 35: Support the Icahn nominees and vote Gold Card

    Forest -Patent •-Current -Icahn Support 32ForestLaboratories nominees representation expirations, Labs the board Icahn atnot needs critical have nominees upgovernment needs independent will to succeeded juncture the benefit Icahn task and nominees exclusion vote and of in Forest dealing similar expe

Forest Laboratories — Proxy Contest (July 2011) on 6ix